RxDoctor Payments Data

Chike Okolocha, DO

Family Medicine · Valparaiso, INNPI 1851915342

Payments from drug & device makers

$6,507in general payments, 2019–2025

Across 258 payments — averaging $25.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • AstraZeneca$858
  • AbbVie$684
  • Otsuka America Pharmaceutical, Inc.$411
  • Novo Nordisk$364
  • Boehringer Ingelheim$325
  • plus $3K from 34 others

What the payments were for

  • Speaking & faculty fees$1,24019%
  • Food & beverage$5,26781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,507 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$29,026
Medicare patients
236
Services billed
727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bupropion XlBupropion Hcl12$331
Hydroxyzine Hcl16$324
Doxycycline Hyclate34$272
Triamcinolone Acetonide18$225
Methylprednisolone55$222
ClopidogrelClopidogrel Bisulfate11$221
Gabapentin20$219
Tamsulosin Hcl19$215
Dicyclomine Hcl12$193
Cephalexin21$190
Levothyroxine Sodium20$179
Metoprolol Succinate18$179
Omeprazole15$177
Azithromycin66$167
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav25$157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCLevothyroxine Sodium$50$17920 claims
Almatica Pharma LLCSertraline Hcl$72$15120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Valparaiso

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →